Membership Overview
New Stimulant Formulations Approved for ADHD
June 23, 2017   

The FDA has approved two new stimulant formulations for the treatment of attention deficit hyperactivity disorder (ADHD)...
 Continue reading (Members only)
Pediatric Suicide: Age Matters
June 20, 2017   

In the United States, the 4th leading cause of death among children age 5-14 years is suicide. In this study, Peyre and colleagues compared risk factors for suicide attempt in children and adolescents...
 Continue reading
Recall: Paliperidone Extended-Release Tablets
June 16, 2017   

Teva Pharmaceuticals has issued a voluntary recall of a single lot of paliperidone extended-release tablets...
 Continue reading (Members only)
Highlights from the 2017 APA Annual Meeting
June 8, 2017   

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.
 Continue reading
2-Month Dose of Injectable Atypical Antipsychotic Approved
June 6, 2017   

The U.S. Food and Drug Administration (FDA) has approved a new 2-month dose of an extended-release injectable atypical antipsychotic...
 Continue reading (Members only)
Maternal and Postpartum Depression: Risk Factors, Mortality, and Child Outcomes
May 31, 2017   

Depression during the postpartum period is not uncommon, with prevalence rates as high as 20% (and perhaps even more prevalent in low-income countries). Recent years have called for increased recognition of postpartum depression, reduction of associated stigma, and support for new mothers in need of treatment...
 Continue reading
No Evidence for Negative Long-Term Effect of Antipsychotic Treatment in Schizophrenia
May 17, 2017   

Although antipsychotics have established efficacy for the acute control of positive symptoms of psychosis, there has been concern that the long-term use of these agents may have negative neurological consequences, such as reduced brain volume and sensitization of dopamine receptors...
 Continue reading (Members only)
Antidepressants and Risk for Autism, ADHD
May 12, 2017   

Recently published studies suggests that mothers' use of antidepressants during early pregnancy does not increase the risk of their children developing autism or attention deficit hyperactivity disorder, conditions previously associated with these medications....
 Continue reading (Members only)
New Brief Screening Tool for Adult ADHD
May 9, 2017   

Researchers affiliated with the World Health Organization (WHO) have developed a brief scale that can reliably screen for attention-deficit/hyperactivity disorder in most adults — using just six straight forward questions...
 Continue reading (Members only)
Results from the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study
May 3, 2017   

Effectively treating major depressive disorder (MDD) is commonly an exercise in trial-and-error and, unfortunately, it takes time (6-12 weeks) in order to deem a particular treatment ineffective before trying a different treatment strategy...
 Continue reading (Members only)
Top of Page